AMPLIA THERAPEUTICS LIMITED - Announcements

2.08%

23.5¢

Market Cap $116.7M

Healthcare Biotechnology

Amplia Therapeutics Limited is an Australia-based clinical-stage, drug development... Amplia Therapeutics Limited is an Australia-based clinical-stage, drug development company. The Company is focused on developing proprietary, orally available, small molecule Focal Adhesion Kinase (FAK) inhibitors as candidate drugs for the treatment of cancer and various fibrotic diseases. The Company's pipeline includes narmafotinib (AMP945) and AMP886. narmafotinib is a selective and potent inhibitor of FAK and is in clinical development for pancreatic cancer and advanced preclinical development for idiopathic pulmonary fibrosis (IPF). The Company's second pipeline drug, AMP886, inhibits FAK and inhibits two key disease drug targets (VEGFR3 and FLT3). This drug is being evaluated in preclinical models of cancer. Its fibrosis program uses its FAK inhibitors to block fibrosis and cell migration in cancers. Its cancer Program is directed at using its FAK inhibitors to block FAK activity in the cancer cells and the surrounding tissue and therefore block survival/proliferation signals.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile

See benefits

Announcements

Filter Results

All Price Sensitive Only

ATX	Change of Director's Interest - Dr C Behrenbruch - Placement		17/09/19	131.96KB	Share
ATX	Change of Director's Interest - Dr Warwick Tong, Placement		17/09/19	133.07KB	Share
ATX	Placement Cleansing Notice		17/09/19	107.79KB	Share
ATX	App 3B Placement Shares and Options to Directors and Mgt		17/09/19	231.16KB	Share
ATX	Amplia Therapeutics Provides Manufacturing Update		02/09/19	114.13KB	Share
ATX	Results of Annual General Meeting		30/08/19	139.52KB	Share
ATX	Change of Director's Interest - S Wilkinson - Options Lapsed		21/08/19	130.44KB	Share
ATX	Amplia Therapeutics - Quarterly Update		12/08/19	291.29KB	Share
ATX	Change of Director's Interest - Dr Warwick Tong Rights Issue		05/08/19	131.85KB	Share
ATX	Change of Director's Interest - Dr Chris Burns, Rights Issue		05/08/19	131.18KB	Share
ATX	Change of Director's Interest - Andrew Cooke, Rights Issue		05/08/19	132.97KB	Share
ATX	Appendix 4C - Quarterly Cash Flow Report - June 2019 Qtr	PRICE SENSITIVE	31/07/19	191.95KB	Share
ATX	RightsIssue Participation Supports Clinical-Enabling Studies	PRICE SENSITIVE	31/07/19	106.94KB	Share
ATX	Amplia Therapeutics - Bioshares Presentation July 2019		25/07/19	1.18MB	Share
ATX	Appendix 4G - Key to Corporate Governance Disclosures		25/07/19	149.5KB	Share
ATX	2019 Corporate Governance Statement		25/07/19	120.98KB	Share
ATX	Notice of Annual General Meeting/Proxy Form		25/07/19	494.45KB	Share
ATX	Annual Report to Shareholders - YE 31 March 2019		25/07/19	1.02MB	Share
ATX	Amplia Therapeutics Reports Lead Candidate Preclinical Data	PRICE SENSITIVE	23/07/19	230.93KB	Share
ATX	Amplia to present to Bioshares Biotech Summit		22/07/19	102.65KB	Share
ATX	Update - July 2019 Newsletter		09/07/19	416.69KB	Share
ATX	Letter to Shareholders - Rights Issue		01/07/19	86.95KB	Share
ATX	Appendix 3B - Rights Issue		28/06/19	218.95KB	Share
ATX	Rights Issue Prospectus	PRICE SENSITIVE	28/06/19	350.41KB	Share
ATX	Financial Report Year Ended 31 March 2019		27/06/19	1002.2KB	Share
ATX	Dr John Lambert appointed as new CEO	PRICE SENSITIVE	24/06/19	116.58KB	Share
ATX	Preliminary Rights Issue Details		17/06/19	116.24KB	Share
ATX	Placement Cleansing Notice		14/06/19	108.06KB	Share
ATX	Appendix 3B - Placement $360k		14/06/19	208.58KB	Share
ATX	Capital Raising for Clinical-Enabling Studies	PRICE SENSITIVE	12/06/19	104.96KB	Share
ATX	Preliminary Final Report - Year Ended 31 March 2019	PRICE SENSITIVE	29/05/19	141.78KB	Share
ATX	Appendix 4C - Quarterly Statement of Cash Flows	PRICE SENSITIVE	30/04/19	162.91KB	Share
ATX	European Patent Completes IP Protection in Major Markets	PRICE SENSITIVE	01/04/19	116.22KB	Share
ATX	Amplia Expands Advisory Board		11/03/19	118.35KB	Share
ATX	Update - February 2019 Newsletter		12/02/19	656.37KB	Share
ATX	Appendix 4C - December 2018 Quarter Cashflow Statement	PRICE SENSITIVE	29/01/19	161.87KB	Share
ATX	App 4D Half Year Accounts 30 Sep 2018	PRICE SENSITIVE	29/11/18	702.6KB	Share
ATX	Change of Director's Interest - Wilkinson - Options Expired		13/11/18	132.62KB	Share
ATX	Change of Director's Interest Notice - Andrew Cooke		07/11/18	131.33KB	Share
ATX	Appendix 4C - quarterly	PRICE SENSITIVE	30/10/18	213.29KB	Share
ATX	Amplia Investor Introduction		05/09/18	2.86MB	Share
ATX	Change of Name to Amplia Therapeutics Limited - ATX		05/09/18	145.76KB	Share
ATX	Change of Director's Interest - Cooke - Options		04/09/18	132.69KB	Share
ATX	Change of Director's Interest - Peach - Options		04/09/18	135.57KB	Share
ATX	Change of Director's Interest - Wilkinson - Options		04/09/18	135.99KB	Share
ATX	Appendix 3B - Options		04/09/18	211.34KB	Share
ATX	Results of Annual General Meeting		30/08/18	138.61KB	Share
ATX	Annual General Meeting Venue		28/08/18	204.48KB	Share
ATX	Response to ASX Query	PRICE SENSITIVE	14/08/18	591.8KB	Share
ATX	US Media Coverage - Mr Chris Collins		09/08/18	108.09KB	Share
ATX	Innate-Amplia Investor Introduction		07/08/18	5.12MB	Share
ATX	Appendix 4C - June 2018 Quarter Cashflow Statement	PRICE SENSITIVE	30/07/18	169.64KB	Share
ATX	Appendix 4G - Key to Corporate Governance Disclosures		26/07/18	150.05KB	Share
ATX	Corporate Governance Statement		26/07/18	138.43KB	Share
ATX	Annual Report to shareholders - YE 31 March 2018		26/07/18	551.09KB	Share
ATX	Notice of Annual General Meeting/Proxy Form		26/07/18	509.82KB	Share
ATX	European Patent Granted for Innate's Drug Candidate AMP-886	PRICE SENSITIVE	23/07/18	121.4KB	Share
ATX	Full Year Statutory Accounts - Year Ended 31 March 2018		20/06/18	592.68KB	Share
ATX	Change of Director's Interest Notice - Andrew Cooke		18/06/18	128.24KB	Share
ATX	Preliminary Final Report - Year Ended 31 March 2018	PRICE SENSITIVE	31/05/18	756.28KB	Share
ATX	Dr. Warwick Tong appointed as Chairman		28/05/18	121.08KB	Share
ATX	Notice of Initial Substantial Holder CTxCRC Ltd and CTxT P/L		28/05/18	126.08KB	Share
ATX	Change of Registered Office and Principal Place of Business		28/05/18	114.46KB	Share
ATX	Becoming a substantial holder - M and T Devlin 34th Avenue		14/05/18	103.9KB	Share
ATX	Becoming a Substantial Holder - Christian Behrenbruch		11/05/18	90.04KB	Share
ATX	Investor Presentation and Conference Call Recording		10/05/18	116.03KB	Share
ATX	Investor Presentation and Conference Call		09/05/18	1.67MB	Share
ATX	Change in Substantial Holding - Christopher Collins		09/05/18	117.91KB	Share
ATX	Final Director's Interest Notice - Andrew Sneddon		04/05/18	122.45KB	Share
ATX	Final Director's Interest Notice - Elizabeth Hopkins		04/05/18	120.73KB	Share
ATX	Final Director's Interest Notice - Chris Collins		04/05/18	120.72KB	Share
ATX	Final Director's Interest Notice - Michael Quinn		04/05/18	123.81KB	Share
ATX	Initial Director's Interest Notice - Andrew Cooke		04/05/18	115.55KB	Share
ATX	Initial Director's Interest Notice - Christopher Burns		04/05/18	122.15KB	Share
ATX	Initial Director's Interest Notice - Warwick Tong		04/05/18	122.38KB	Share
ATX	Initial Director's Interest Notice - Christian Behrenbruch		04/05/18	125.72KB	Share
ATX	Amplia Acquisition Completed and New Board Appointments		04/05/18	134.85KB	Share
ATX	Appendix 3B - Amplia Acquisition		04/05/18	210KB	Share
ATX	App 4C - March 2018 Quarterly Cash Flow Report	PRICE SENSITIVE	30/04/18	158.74KB	Share
ATX	Results of Meeting		26/04/18	138.38KB	Share
ATX	Acquisition of Amplia Therapeutics - Questions and Answers		06/04/18	167.3KB	Share
ATX	Consolidation/Split - IIL		28/03/18	51.93KB	Share
ATX	Notice of General Meeting/Proxy Form		28/03/18	644.52KB	Share
ATX	Focus on Immuno-Oncology & Acquisition of 2 Drug Candidates	PRICE SENSITIVE	23/03/18	224.03KB	Share
ATX	S&P DJ Indices Announces March Quarterly Rebalance	PRICE SENSITIVE	09/03/18	201.26KB	Share
ATX	Appendix 4C - December 2017 Quarter	PRICE SENSITIVE	31/01/18	648.21KB	Share
ATX	Half Yearly Report and Accounts - HY ending 30 Sep 2017	PRICE SENSITIVE	30/11/17	1.22MB	Share
ATX	Appendix 4C - September 2017 Quarter Cashflows	PRICE SENSITIVE	30/10/17	650.42KB	Share
ATX	Corporate Update	PRICE SENSITIVE	20/10/17	480.31KB	Share
ATX	Change of Director's Interest Notice - Chris Collins		26/09/17	605.41KB	Share
ATX	Results of Meeting - Annual General Meeting		30/08/17	504.68KB	Share
ATX	App 4C - Quarterly Statement of Cashflows - June 2017 Qtr	PRICE SENSITIVE	28/07/17	647.2KB	Share
ATX	App 4G - Key to Corporate Governance Disclosures		28/07/17	219.37KB	Share
ATX	2017 Corporate Governance Statement		28/07/17	386.64KB	Share
ATX	Annual Report to Shareholders - YE 31 March 2017		27/07/17	566.47KB	Share
ATX	Notice of Annual General Meeting/Proxy Form		27/07/17	804.39KB	Share
ATX	Change of Director's Interest Notice - Simon Wilkinson		24/07/17	605.7KB	Share
ATX	No Change in Trial Outcome Following Additional Analysis	PRICE SENSITIVE	21/07/17	500.52KB	Share
ATX	Response to ASX Price Query	PRICE SENSITIVE	11/07/17	169.59KB	Share
ATX	Change of Director's Interest Notice - A. Sneddon		29/06/17	618.37KB	Share

ATX Change of Director's Interest - Dr C Behrenbruch - Placement
17/09/19		131.96KB	Share
ATX Change of Director's Interest - Dr Warwick Tong, Placement
17/09/19		133.07KB	Share
ATX Placement Cleansing Notice
17/09/19		107.79KB	Share
ATX App 3B Placement Shares and Options to Directors and Mgt
17/09/19		231.16KB	Share
ATX Amplia Therapeutics Provides Manufacturing Update
02/09/19		114.13KB	Share
ATX Results of Annual General Meeting
30/08/19		139.52KB	Share
ATX Change of Director's Interest - S Wilkinson - Options Lapsed
21/08/19		130.44KB	Share
ATX Amplia Therapeutics - Quarterly Update
12/08/19		291.29KB	Share
ATX Change of Director's Interest - Dr Warwick Tong Rights Issue
05/08/19		131.85KB	Share
ATX Change of Director's Interest - Dr Chris Burns, Rights Issue
05/08/19		131.18KB	Share
ATX Change of Director's Interest - Andrew Cooke, Rights Issue
05/08/19		132.97KB	Share
ATX Appendix 4C - Quarterly Cash Flow Report - June 2019 Qtr
31/07/19	PRICE SENSITIVE	191.95KB	Share
ATX RightsIssue Participation Supports Clinical-Enabling Studies
31/07/19	PRICE SENSITIVE	106.94KB	Share
ATX Amplia Therapeutics - Bioshares Presentation July 2019
25/07/19		1.18MB	Share
ATX Appendix 4G - Key to Corporate Governance Disclosures
25/07/19		149.5KB	Share
ATX 2019 Corporate Governance Statement
25/07/19		120.98KB	Share
ATX Notice of Annual General Meeting/Proxy Form
25/07/19		494.45KB	Share
ATX Annual Report to Shareholders - YE 31 March 2019
25/07/19		1.02MB	Share
ATX Amplia Therapeutics Reports Lead Candidate Preclinical Data
23/07/19	PRICE SENSITIVE	230.93KB	Share
ATX Amplia to present to Bioshares Biotech Summit
22/07/19		102.65KB	Share
ATX Update - July 2019 Newsletter
09/07/19		416.69KB	Share
ATX Letter to Shareholders - Rights Issue
01/07/19		86.95KB	Share
ATX Appendix 3B - Rights Issue
28/06/19		218.95KB	Share
ATX Rights Issue Prospectus
28/06/19	PRICE SENSITIVE	350.41KB	Share
ATX Financial Report Year Ended 31 March 2019
27/06/19		1002.2KB	Share
ATX Dr John Lambert appointed as new CEO
24/06/19	PRICE SENSITIVE	116.58KB	Share
ATX Preliminary Rights Issue Details
17/06/19		116.24KB	Share
ATX Placement Cleansing Notice
14/06/19		108.06KB	Share
ATX Appendix 3B - Placement $360k
14/06/19		208.58KB	Share
ATX Capital Raising for Clinical-Enabling Studies
12/06/19	PRICE SENSITIVE	104.96KB	Share
ATX Preliminary Final Report - Year Ended 31 March 2019
29/05/19	PRICE SENSITIVE	141.78KB	Share
ATX Appendix 4C - Quarterly Statement of Cash Flows
30/04/19	PRICE SENSITIVE	162.91KB	Share
ATX European Patent Completes IP Protection in Major Markets
01/04/19	PRICE SENSITIVE	116.22KB	Share
ATX Amplia Expands Advisory Board
11/03/19		118.35KB	Share
ATX Update - February 2019 Newsletter
12/02/19		656.37KB	Share
ATX Appendix 4C - December 2018 Quarter Cashflow Statement
29/01/19	PRICE SENSITIVE	161.87KB	Share
ATX App 4D Half Year Accounts 30 Sep 2018
29/11/18	PRICE SENSITIVE	702.6KB	Share
ATX Change of Director's Interest - Wilkinson - Options Expired
13/11/18		132.62KB	Share
ATX Change of Director's Interest Notice - Andrew Cooke
07/11/18		131.33KB	Share
ATX Appendix 4C - quarterly
30/10/18	PRICE SENSITIVE	213.29KB	Share
ATX Amplia Investor Introduction
05/09/18		2.86MB	Share
ATX Change of Name to Amplia Therapeutics Limited - ATX
05/09/18		145.76KB	Share
ATX Change of Director's Interest - Cooke - Options
04/09/18		132.69KB	Share
ATX Change of Director's Interest - Peach - Options
04/09/18		135.57KB	Share
ATX Change of Director's Interest - Wilkinson - Options
04/09/18		135.99KB	Share
ATX Appendix 3B - Options
04/09/18		211.34KB	Share
ATX Results of Annual General Meeting
30/08/18		138.61KB	Share
ATX Annual General Meeting Venue
28/08/18		204.48KB	Share
ATX Response to ASX Query
14/08/18	PRICE SENSITIVE	591.8KB	Share
ATX US Media Coverage - Mr Chris Collins
09/08/18		108.09KB	Share
ATX Innate-Amplia Investor Introduction
07/08/18		5.12MB	Share
ATX Appendix 4C - June 2018 Quarter Cashflow Statement
30/07/18	PRICE SENSITIVE	169.64KB	Share
ATX Appendix 4G - Key to Corporate Governance Disclosures
26/07/18		150.05KB	Share
ATX Corporate Governance Statement
26/07/18		138.43KB	Share
ATX Annual Report to shareholders - YE 31 March 2018
26/07/18		551.09KB	Share
ATX Notice of Annual General Meeting/Proxy Form
26/07/18		509.82KB	Share
ATX European Patent Granted for Innate's Drug Candidate AMP-886
23/07/18	PRICE SENSITIVE	121.4KB	Share
ATX Full Year Statutory Accounts - Year Ended 31 March 2018
20/06/18		592.68KB	Share
ATX Change of Director's Interest Notice - Andrew Cooke
18/06/18		128.24KB	Share
ATX Preliminary Final Report - Year Ended 31 March 2018
31/05/18	PRICE SENSITIVE	756.28KB	Share
ATX Dr. Warwick Tong appointed as Chairman
28/05/18		121.08KB	Share
ATX Notice of Initial Substantial Holder CTxCRC Ltd and CTxT P/L
28/05/18		126.08KB	Share
ATX Change of Registered Office and Principal Place of Business
28/05/18		114.46KB	Share
ATX Becoming a substantial holder - M and T Devlin 34th Avenue
14/05/18		103.9KB	Share
ATX Becoming a Substantial Holder - Christian Behrenbruch
11/05/18		90.04KB	Share
ATX Investor Presentation and Conference Call Recording
10/05/18		116.03KB	Share
ATX Investor Presentation and Conference Call
09/05/18		1.67MB	Share
ATX Change in Substantial Holding - Christopher Collins
09/05/18		117.91KB	Share
ATX Final Director's Interest Notice - Andrew Sneddon
04/05/18		122.45KB	Share
ATX Final Director's Interest Notice - Elizabeth Hopkins
04/05/18		120.73KB	Share
ATX Final Director's Interest Notice - Chris Collins
04/05/18		120.72KB	Share
ATX Final Director's Interest Notice - Michael Quinn
04/05/18		123.81KB	Share
ATX Initial Director's Interest Notice - Andrew Cooke
04/05/18		115.55KB	Share
ATX Initial Director's Interest Notice - Christopher Burns
04/05/18		122.15KB	Share
ATX Initial Director's Interest Notice - Warwick Tong
04/05/18		122.38KB	Share
ATX Initial Director's Interest Notice - Christian Behrenbruch
04/05/18		125.72KB	Share
ATX Amplia Acquisition Completed and New Board Appointments
04/05/18		134.85KB	Share
ATX Appendix 3B - Amplia Acquisition
04/05/18		210KB	Share
ATX App 4C - March 2018 Quarterly Cash Flow Report
30/04/18	PRICE SENSITIVE	158.74KB	Share
ATX Results of Meeting
26/04/18		138.38KB	Share
ATX Acquisition of Amplia Therapeutics - Questions and Answers
06/04/18		167.3KB	Share
ATX Consolidation/Split - IIL
28/03/18		51.93KB	Share
ATX Notice of General Meeting/Proxy Form
28/03/18		644.52KB	Share
ATX Focus on Immuno-Oncology & Acquisition of 2 Drug Candidates
23/03/18	PRICE SENSITIVE	224.03KB	Share
ATX S&P DJ Indices Announces March Quarterly Rebalance
09/03/18	PRICE SENSITIVE	201.26KB	Share
ATX Appendix 4C - December 2017 Quarter
31/01/18	PRICE SENSITIVE	648.21KB	Share
ATX Half Yearly Report and Accounts - HY ending 30 Sep 2017
30/11/17	PRICE SENSITIVE	1.22MB	Share
ATX Appendix 4C - September 2017 Quarter Cashflows
30/10/17	PRICE SENSITIVE	650.42KB	Share
ATX Corporate Update
20/10/17	PRICE SENSITIVE	480.31KB	Share
ATX Change of Director's Interest Notice - Chris Collins
26/09/17		605.41KB	Share
ATX Results of Meeting - Annual General Meeting
30/08/17		504.68KB	Share
ATX App 4C - Quarterly Statement of Cashflows - June 2017 Qtr
28/07/17	PRICE SENSITIVE	647.2KB	Share
ATX App 4G - Key to Corporate Governance Disclosures
28/07/17		219.37KB	Share
ATX 2017 Corporate Governance Statement
28/07/17		386.64KB	Share
ATX Annual Report to Shareholders - YE 31 March 2017
27/07/17		566.47KB	Share
ATX Notice of Annual General Meeting/Proxy Form
27/07/17		804.39KB	Share
ATX Change of Director's Interest Notice - Simon Wilkinson
24/07/17		605.7KB	Share
ATX No Change in Trial Outcome Following Additional Analysis
21/07/17	PRICE SENSITIVE	500.52KB	Share
ATX Response to ASX Price Query
11/07/17	PRICE SENSITIVE	169.59KB	Share
ATX Change of Director's Interest Notice - A. Sneddon
29/06/17		618.37KB	Share

REFRESH

First 2 3 4 5 6

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 23.5¢		Change -0.005(2.08%)		Mkt cap ! $116.7M

Open	High	Low	Value	Volume
24.0¢	24.0¢	23.5¢	$111.3K	464.2K

Buyers (Bids)

No.	Vol.	Price($)
27	501199	23.5¢

Sellers (Offers)

Price($)	Vol.	No.
24.0¢	36490	5

View Market Depth

No.	Vol.	Price($)
26	496944	0.235
23	1299413	0.230
18	886810	0.225
17	458796	0.220
4	287203	0.215

Price($)	Vol.	No.
0.240	36490	5
0.245	380474	9
0.250	462659	11
0.255	170793	5
0.260	297200	6

Last trade - 10.29am 01/08/2025 (20 minute delay)


Last 23.3¢		Change -0.005 ( 2.76 %)
Open	High	Low	Volume
24.0¢	24.0¢	23.0¢	1022966
Last updated 10.47am 01/08/2025 ?

ATX (ASX) Chart

AMPLIA THERAPEUTICS LIMITED - Announcements

Corporate Spotlight
Not Yet Available

Announcements

Buyers (Bids)

Sellers (Offers)

Codeifai looks to ride AI wave as Quantum Computing becomes a necessity

Prospect Resources: Replicating the success of Arcadia with ~1b tonne copper ore target

Infini Resources appoints Rohan Bone as CEO ahead of Phase 2 campaign

Resolution Minerals appoints industry experts to fast-track US growth strategy

Top Stories

AMPLIA THERAPEUTICS LIMITED - Announcements

Corporate SpotlightNot Yet Available

Announcements

Buyers (Bids)

Sellers (Offers)

Codeifai looks to ride AI wave as Quantum Computing becomes a necessity

Prospect Resources: Replicating the success of Arcadia with ~1b tonne copper ore target

Infini Resources appoints Rohan Bone as CEO ahead of Phase 2 campaign

Resolution Minerals appoints industry experts to fast-track US growth strategy

Top Stories

Corporate Spotlight
Not Yet Available